SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented during a poster presentation at the recent ObesityWeek 2018 conference in Nashville, Tennessee.
The poster presentation, titled "Dual Vagus Neuromodulation Improves Glycemic Control in Obese Rat and Pig Models of Type 2 Diabetes," discussed a proprietary technique developed by ReShape Lifesciences that utilizes the Company's vBlocTM technology to stimulate nerves feeding into the pancreas while simultaneously blocking nerves feeding into the liver. The goal of the procedure is to increase release of the body's natural insulin and to prevent glucose release from the liver into the blood stream. Ultimately, the procedure could reduce the need for injectable insulin and drug therapies by lowering blood glucose in patients with type 2 diabetes mellitus.
Data presented in the poster highlighted results of experiments that were conducted in obese type 2 diabetic rats and in a type 2 diabetic pig model. When subjected to block and stimulation following ingestion of glucose, blood glucose of the diabetic pigs was significantly decreased compared to the control. In an additional obese and type 2 diabetic-Zucker rat study, a similar and significant result was observed compared to the control.
"If this data can be replicated and translated into human studies, this would be a genuinely new approach for treatment of type 2 diabetes mellitus," stated Dr. Charles Billington, MD, Chief, Section of Endocrinology and Metabolism, Minneapolis VA Health Care System and lead study investigator.
The studies suggest a novel, reversible and adjustable neuromodulation technique for the potential treatment of patients with type 2 diabetes mellitus. The Company believes that in combination with a continuous glucose sensor or monitoring device, this proprietary technology could provide a vital tool to offer neuromodulation treatment and glucose reduction for type 2 diabetic patients.
ReShape Lifesciences™ has several issued and pending U.S. and foreign patents for this proprietary technology.
About ReShape Lifesciences Inc.
ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements that the procedure could reduce the need for injectable insulin and drug therapies by lowering blood glucose in patients with type 2 diabetes mellitus and that the technology could provide a vital tool to offer neuromodulation treatment and glucose reduction for type 2 diabetic patients. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisitions of ReShape Medical Inc. and BarioSurg, Inc.; risks related to the U.S. Food and Drug Administration's announcement, including updates thereto, to alert health care providers of unanticipated deaths involving the ReShape Balloon; our proposed ReShape Vest product may not be successfully developed and commercialized; our ability to continue as a going concern if we are unsuccessful in our pursuit of various funding options; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements and remain listed on Nasdaq; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed April 2, 2018 and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACT:
Investor Contact:Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
949-429-6680 x106
syoungstrom@reshapelifesci.com
or
Debbie Kaster
Investor Relations
Gilmartin Group
415-937-5403
debbie@gilmartinir.com
SOURCE: ReShape Lifesciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/528930/ReShape-Lifesciences-Presents-New-Data-on-Proprietary-Technology-for-Type-2-Diabetes
